793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Georgina V. Long; Andrew J. Spillane; Thomas E. Pennington; Kerwin F. Shannon; Jonathan R. Stretch; Maria Gonzalez; R.P.M. Saw; Serigne Lo; Richard A Scolyer; Alexander M. Menzies

doi:10.1016/j.annonc.2022.07.919

Related publications

Article2020

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

Maria Gonzalez, Alexander M. Menzies, Thomas E. Pennington, Robyn P.M. Saw, Andrew J. Spillane, Jonathan R. Stretch, Kerwin F. Shannon, Sydney Ch’ng, Omgo E. Nieweg, Maria Cruzado Rojas, Monica Osorio, Robert V. Rawson, Peter M. Ferguson, Helen Rizos, Serigne Lo, Richard A Scolyer, Georgina V. Long

Article2024

Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.

Ines Esteves Domingues Pires Da Silva, Jordan W. Conway, Akshaya Ramanathan, Laura Smith, Robert V. Rawson, Piyush Grover, Nigel Maher, Jorja Braden, Maria Gonzalez, Umaimainthan Palendira, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long

Article2024

133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response

I. Pires da Silva, Jordan W. Conway, Linda Smith, Anand Ramanathan, Nurudeen A. Adegoke, R. Rawson, P. Grover, Nigel Maher, Jorja Braden, M. Gonzalez, Umaimainthan Palendira, A.M. Menzies, Richard A Scolyer, G.V. Long

Article2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen,

Article2024

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long

793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Discussion(0)

Related publications

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.

133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.